Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Finished Goods (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Finished Goods for 6 consecutive years, with $3.5 million as the latest value for Q3 2018.

  • On a quarterly basis, Finished Goods fell 22.92% to $3.5 million in Q3 2018 year-over-year; TTM through Sep 2018 was $3.5 million, a 22.92% decrease, with the full-year FY2017 number at $5.0 million, up 42.8% from a year prior.
  • Finished Goods was $3.5 million for Q3 2018 at Theravance Biopharma, down from $4.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $7.5 million in Q3 2014 to a low of $2.0 million in Q2 2017.
  • A 5-year average of $4.3 million and a median of $4.6 million in 2017 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: plummeted 58.75% in 2016, then soared 99.6% in 2018.
  • Theravance Biopharma's Finished Goods stood at $5.6 million in 2014, then plummeted by 43.71% to $3.1 million in 2015, then rose by 12.44% to $3.5 million in 2016, then surged by 42.8% to $5.0 million in 2017, then plummeted by 30.29% to $3.5 million in 2018.
  • Per Business Quant, the three most recent readings for TBPH's Finished Goods are $3.5 million (Q3 2018), $4.0 million (Q2 2018), and $4.6 million (Q1 2018).